Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Ireland
  4. Irish Stock Exchange
  5. Elan Corporation Ltd
  6. News
  7. Summary
    DRX   IE0003072950

ELAN CORPORATION LTD

(DRX)
SummaryChartsNewsCompany 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

J&J stake sale clouds Royalty bid for Elan

04/18/2013 | 02:35pm EDT

DUBLIN/NEW YORK (Reuters) - U.S. healthcare firm Johnson & Johnson (>> Johnson & Johnson) cut its stake in Elan Corp on Thursday in a move that clouds prospects for a $7.3 billion (4.7 billion pounds) takeover bid for the Irish drugmaker.

DUBLIN/NEW YORK (Reuters) - U.S. healthcare firm Johnson & Johnson (>> Johnson & Johnson) cut its stake in Elan Corp <ELN.N> on Thursday in a move that clouds prospects for a $7.3 billion (4.7 billion pounds) takeover bid for the Irish drugmaker.

U.S. investment firm Royalty Pharma on Monday made an improved $12 per share bid for Elan, which has rejected its suitor's overtures and wants to remain an independent company.

However, that offer depended on the outcome of a $1 billion share buyback being conducted by the Irish firm.

Royalty had urged Elan's shareholders to tender shares at between $11.75 and $12 apiece and warned that if they did not, it would reduce its offer.

Elan (>> Elan Corporation, plc) said on Thursday it had bought back the targeted amount of stock at the bottom of its indicative price range of $11.25 to $13, with Johnson & Johnson (J&J) accounting for 92.3 percent of all shares purchased.

J&J, whose stake in Elan has fallen to 4.9 percent from 18 percent, did not give a reason for selling shares in Elan, but said it would make a $213 million gain on its 2009 investment.

Royalty said that as a result of the pricing of the buyback, it would lower its offer for Elan to $11.25 a share.

At 1740 GMT, however, Elan's shares were up 0.2 percent at $11.9 in New York. Analysts were divided whether this signalled confidence in Elan's management, or speculation that Royalty would eventually return with a higher bid.

"It's a strong message that the shareholder base of Elan is not thinking about tendering at the $13 level," said Berenberg Bank analyst Adrian Howd, referring to the top end of the price range proposed by Elan for its share buyback.

Elan sold its 50 percent interest in lucrative multiple sclerosis drug Tysabri for $3.25 billion plus future royalties to U.S. partner Biogen Idec (>> Biogen Idec Inc.) in February, and wants to spend the bulk of the money on acquisitions.

Royalty argues Elan's management does not have a track record of deals, and has urged the Irish firm's shareholders to accept its cash offer. It wants to add the royalty rights to Tysabri - worth hundreds of millions of dollars annually - to its large stable of royalty streams.

Elan said just 4 percent of shares were tendered in the price range recommended by Royalty.

Mirabaud Securities analyst Nick Turner was surprised more Elan shareholders had not tendered shares towards the top end of the indicative range.

"Whether they believe they can get a better return out of Elan under current management ... that is not an argument that holds water with me," he said.

The volume of Elan shares changing hands had more than trebled by late morning trading in New York compared with the day before, which some analysts saw as a sign that dealers are still hoping for a higher bid for the company.

(Additional reporting by Ransdell Pierson; Editing by Mark Potter)

By Padraic Halpin and Jessica Toonkel

Stocks treated in this article : Biogen Idec Inc., Elan Corporation, plc, Johnson & Johnson

© Reuters 2013
Stocks mentioned in the article
ChangeLast1st jan.
BASE CO., LTD. 1.75% 4935 End-of-day quote.-19.76%
BASE, INC. -3.36% 1525 End-of-day quote.-21.88%
BIOGEN INC. -0.29% 325.4 Delayed Quote.33.28%
ELAN CORPORATION LTD -0.39% 12.71 End-of-day quote.0.00%
JOHNSON & JOHNSON 1.06% 171.79 Delayed Quote.9.16%
ROYALTY PHARMA PLC -0.07% 40.33 Delayed Quote.-19.42%
All news about ELAN CORPORATION LTD
2014With eye on tax rates, Horizon Pharma buys Ireland's Vidara
RE
2013Ex-SAC manager Martoma fails to end part of insider case
RE
2013ELAN CORPORATION, PLC : Perrigo Company and Elan Corporation Plc Receive Irish H..
PU
2013Ex-SAC trader points to Cohen testimony in insider trading case
RE
2013ELAN CORPORATION, PLC : Elan Announces Shareholder Approval of its Acquisition b..
BU
2013Elan wins shareholder approval to complete Perrigo sale
RE
2013The prosecutors with SAC Capital in their crosshairs
RE
2013ELAN CORPORATION, PLC : Elan Reports Third Quarter 2013 Financial Results
BU
2013EXCLUSIVE - TPG-BACKED APTALIS PHARM : sources
RE
2013ELAN CORPORATION, PLC : Elan Announces Webcast of Third Quarter 2013 Financial R..
BU
More news
Chart ELAN CORPORATION LTD
Duration : Period :
Elan Corporation Ltd Technical Analysis Chart | DRX | IE0003072950 | MarketScreener
Sector and Competitors
1st jan.Capi. (M$)
ELAN CORPORATION LTD0.00%0
MODERNA, INC.233.90%88 312
LONZA GROUP AG24.05%53 538
IQVIA HOLDINGS INC.39.02%47 022
CELLTRION, INC.-25.21%32 170
SEAGEN INC.-16.87%28 525